EWM
ACAD icon

Empirical Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Empirical Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Buy
15,489
+2,566
+20% +$56.5K 0.01% 783
2026
Q1 		$288K Buy
12,923
+3,026
+31% +$72.3K 0.01% 810
2025
Q4 		$264K Buy
+9,897
New +$237K ﹤0.01% 744

Other funds holding ACAD

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Empirical Wealth Management's ACAD Position: Q2 2026 in Review

Empirical Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q2 2026, buying an estimated $56.5K and bringing the position to 15,489 shares worth $392K. The position accounts for 0.01% of the portfolio, ranked #783.

Empirical Wealth Management first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Empirical Wealth Management held 15,489 shares of Acadia Pharmaceuticals worth $392K as of Q2 2026.
  • Empirical Wealth Management bought 2,566 Acadia Pharmaceuticals shares in Q2 2026, an estimated $56.5K.
  • Acadia Pharmaceuticals made up 0.01% of Empirical Wealth Management's portfolio in Q2 2026, its #783 holding.
  • Empirical Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.